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Background: The 2013 American College of Cardiology/American Heart Association Cardiovascular Prevention Guidelines utilize new 
pooled cohort equations (PCE) to predict 10-year risk of atherosclerotic cardiovascular disease (ASCVD) events which form the basis 
of treatment recommendations. We sought to study the level of agreement in predicted ASCVD risk by CAC-score and PCE-calculated 
models and the potential impact on therapy of additional CAC testing.
methods: We studied 687 consecutive patients (mean age 54 years, 72% men) that had a coronary calcium study at our institution. Clinical 
& imaging data were recorded. ASCVD risk was calculated utilizing published PCE-based algorithm. CAC-based risk was categorized by 
previously published recommendations. Risk stratification comparisons were made and level of agreement calculated.
results: In the cohort, mean ASCVD PCE-calculated risk was 5.3% and mean CAC score was 80 Agatston units (AU). Of the intermediate 
PCE-calculated risk (5% to < 7.5%) cohort, 85% had CAC score <100 AU (Table). Of the cohort categorized as Reasonable to Treat per the 
ASCVD prevention guidelines, 40% had a CAC score of 0 AU and an additional 44% had CAC scores >0 but < 100 AU.
conclusion: For the patients with intermediate risk of ASCVD (PCE-calculated risk of 5% to < 7.5%), CAC testing further refines risk 
assessment in a significant number of patients. This can assist clinicians in conducting an evidence-based discussion with their patients to 
determine whether to start therapy.
CAC Score versus ACC/AHA ASCVD Prevention Risk Score: Kappa=0.23 ±0.029
Pooled Risk Score Total
<5% 5-7.49% >=7.5
CAC Score 0-99 Count 416 77 90 583
% within CAC score Category 71.4% 13.2% 15.4% 100.0%
% within Pooled Risk Score Categories 94.5% 84.6% 57.7% 84.9%
100-299 Count 19 9 31 59
% within CAC score Category 32.2% 15.3% 52.5% 100.0%
% within Pooled Risk Score Categories 4.3% 9.9% 19.9% 8.6%
>=300 Count 5 5 35 45
% within CAC score Category 11.1% 11.1% 77.8% 100.0%
% within Pooled Risk Score Categories 1.1% 5.5% 22.4% 6.6%
Total Count 440 91 156 687
% within CAC score Category 64.0% 13.2% 22.7% 100.0%
% within Pooled Risk Score Categories 100.0% 100.0% 100.0% 100.0%
